Health of ageing population Impacts of diet in the elderly s u m m a r y Background: Recent reviews indicate that adherence to a Mediterranean diet may be associated with better cognitive functioning. In assessing these relationships in older individuals, previous studies have not taken into account medication usage that may support or compromise cognitive functioning. Objective: To investigate the association between adherence to a Mediterranean style diet, cognition and medication usage in cognitively healthy older individuals. Design: Data were assessed from individuals aged 60e90 years (mean ¼ 77.8 years, SD ¼ 6.7) from 15 independent living aged care villages around Melbourne, Australia. Participants' diets were assessed using a food frequency questionnaire (FFQ). Cognition was assessed using reaction times from the Swinburne University Computerised Cognitive Assessment Battery (SUCCAB). Prescribed medications were recorded and analysed using binary measures. Cluster analyses were used to group participants in terms of cognitive measures and medications taken. Analyses controlled for age, gender, average daily kilojoule (kJ) intake and medication cluster. Results: The relationship between cognitive speed clusters and medication clusters was significant (Chisquared ¼ 10.63, df ¼ 3, p ¼ 0.014). The odds ratio of 1.533 for average daily food intake suggested that for each additional kilojoule of average daily intake, the odds of belonging to the slower reaction time cluster increased by 53% and odds ratio of 0.573 for Mediterranean diet score suggested that for every additional unit, the odds of belonging to the slower reaction time cluster declined by 43%. The relationship between Mediterranean diet score and cognition was only significant when medication use was taken into account.
Introduction
Diet is considered to be one of the greatest contributors to overall health. The term 'Western diet' is used to describe a diet containing large amounts of red meat, refined sugars, grains, and high fat foods that is common in Western countries. The high levels of saturated fat and trans-fatty acids consumed in this diet have contributed to the obesity epidemic in these countries [1] . Obesity has been linked with impaired cognitive function and an elevated risk of late-onset dementia, such as Alzheimer's disease [2, 3] .
A Western diet and a sedentary lifestyle impacts general health, including increasing the rate of obesity, high blood pressure, high blood triglycerides, high levels of LDL and low levels of HDL cholesterol and insulin resistance. These comorbidities have resulted in an increased incidence of coronary artery disease, diabetes, chronic pain syndrome, inflammatory disease, cardiovascular disease, respiratory disease and end organ damage [4] . The comorbidities including high blood pressure, high cholesterol, insulin resistance and obesity are classified as the metabolic syndrome, and can lead to cognitive impairment [5] . Metabolic syndrome may impair cognition in the elderly, especially in those with inflammation. Metabolic syndrome, particularly in ageing populations, is treated pharmacologically, to reduce blood pressure and cholesterol levels [6] .
The Mediterranean diet (MedDiet) is considered a healthier alternative to the Western diet. The MedDiet is a diet with an abundance of plant foods in the form of fruits, vegetables, breads, other forms of cereals, beans, nuts, seeds, fish and olive oil as its main source of monounsaturated fats; while dairy foods, red meat and chicken are consumed in lower quantities, and red wine is consumed moderately with meals. These foods provide a high intake of b-carotene, vitamin C, tocopherols, omega-3 fatty acids, various minerals and other beneficial substances such as polyphenols and anthocyanins [7, 8] . Adherence to the MedDiet was initially considered relevant to health when it was demonstrated that mortality was reduced within the populations located in the areas of Southern Europe [8, 9] .
Two recent systematic reviews have indicated that the MedDiet may be neuroprotective as well as cognition-enhancing in the shorter term [10, 11] . Additionally this diet is likely to be protective against accelerated cognitive decline and the transition to mild cognitive impairment and dementia. Medications taken by older participants, and how medications may impact the protective effects of a MedDiet had not been assessed.
Within a Western society the use of medications is part of the primary armamentarium to reduce the impact of comorbidities, such as the metabolic syndrome. To this end, in Australia, as in the rest of the developed world, there has been a substantial increase in the use of blood pressure medications and statins to alleviate the effects of the metabolic syndrome. The use of medications and the impact of comorbidities may provide further understanding of the effects of cognitive changes within an ageing population [12] .
The primary aim of this study was to investigate the association of adherence to a Mediterranean style of diet with respect to cognition, while taking into consideration the use of medications. This study utilised the baseline data from a randomised controlled trial investigating the effects of the MedDiet on cognition in cognitively healthy older people living independently within aged care facilities: the Lifestyle Intervention in Independent Living Aged Care (LIILAC) study [ACTRN12614001133628] [13] .
Methods

Recruitment and approval
Participants were aged 60e90 years and living independently in 15 aged care and retirement villages in and around Melbourne, Australia. Recruitment took place between 1 April 2014 and 30 June 2015.
Eligibility criteria
Participants were fluent in written and spoken English. Participants had to obtain the approval of their medical practitioner to be involved in the trial.
Ineligibility criteria
Participants were unable to participate if they had a significant visual impairment, had a neurological or uncontrolled psychiatric disorder, were unable to walk independently and safely, or used illicit drugs or cognitive enhancing medications. Finally, those who had suspected cognitive impairment (defined as a score <24 on the Mini Mental State Examination) or depression (a score >9 on the Geriatric Depression Scale) were also excluded.
Ethical clearance
This study was approved by the Swinburne University Human Research Ethics Committee (project number 2013/057).
Selection criteria were followed in accordance with the published protocol [13] . Figure 1 outlines the recruitment profile of the 105 participants who entered the trial. Five participants left prior to initiation of any assessment. The 100 remaining participants, 28 males and 72 females, were assessed, of whom 93 responded to the question regarding their use of prescription medications. Among these 93 participants, 75% were prescribed more than two medications, 24% more than five medications, and 9% more than seven medications (mean 4.16, SD ¼ 2.17). [14] . The output was utilised to produce a Mediterranean diet score (MedDietS) in accordance with Trichopoulou et al., 2003 [15] . The sexspecific median allows for a comparative cut-off to be made between genders on food consumption [15] . Beneficial foods, such as vegetables, legumes, fruits, nuts, cereals, and fish, were assigned a value of 0 if a person's consumption was below the median, and a score of 1 if it was equal to, or above, the median. Food components detrimental to health, such as meat, poultry, and dairy, consumption above the median was scored as 0, and intake below the median was scored as 1. For alcohol, a score of 1 was given provided consumption was within a specified range. When considering fat intake, the ratio of monounsaturated lipids to polyunsaturated lipids was evaluated, with a higher ratio being more acceptable and a score of 1 allocated accordingly. Kilojoules consumed was also reported within the FFQ. Thus, the total MedDietS ranged from 0 (minimal adherence to the traditional MedDiet) to 9 (maximal adherence) [15] . The SUCCAB is a validated computer-based cognitive battery consisting of eight measures that focus on the cognitive domains that decline with increasing age and includes simple and choice reaction times, immediate and delayed recognition, congruent and incongruent Stroop colour-words, spatial working memory and contextual memory [16] . Speed of response to correctly performed trials was recorded for each of these measures. The analysis was focussed on response time to correctly performed trials; we have argued previously that response time is a particularly sensitive measure of cognitive ageing [16] .
Diet assessment
Abbreviations
Medication assessment
All participants assessed at baseline had been evaluated as cognitively healthy, and during screening, usage of prescription and non-prescription medications was recorded. The medication data were recorded using a binary (Yes/No) measure.
Demographic and morphometric measures
Age, gender, education and smoking status were recorded as part of the study requirements. Height, weight, hip and waist circumference were measured and recorded.
Covariates and preliminary analysis
All food groups were calculated in grams per day and the total daily kilojoules consumed per day was also calculated. Age (in years) was calculated from self-reported birth date. Speed of response to each cognitive task was converted into a Z-score. Age, sex (gender), and daily energy intake were the control variables. Figure 2 shows the variable assessment process.
Statistical analysis
Cluster analyses were used to group 93 participants in terms of their cognitive measures and medications taken. Clustering allows the assignment of participants to groups with similar data patterns for the variables considered. Clustering enables structures to be identified within the data and relies on discriminant analysis to check if the group's differences are statistically significant and if all variables significantly discriminate between groups [17] .
Participants were clustered in terms of their cognitive outcomes, as measured by the SUCCAB reaction time Z-scores for correctly performed trials, utilising Ward's method for hierarchical clustering. The resulting dendrogram suggested two clear SUCCAB cognitive clusters, which were compared in terms of average daily energy intake (kilojoules), MedDietS and age using ANOVA tests, while a comparison in terms of gender was carried out using a crosstab test.
Similarly, participants were clustered in terms of their prescribed medications, again using Ward's method but allowing for the binary nature of these data. The dendrogram suggested four clear clusters (see Fig. 3 ). The relationship between the medication and SUCCAB clusters was investigated using a crosstab test. Finally, hierarchical binary logistic regression analysis was used to determine the importance of MedDiet as a determinant of the cognition clusters, when controlling for medication cluster, age, gender, and average daily energy intake. All analyses were conducted using SPSS Statistics Version 23.
Results
This study investigated the cognitive capabilities of an Australian cohort living in independent living aged care in relation to their adherence to a MedDiet and medication use. Table 1 shows that the mean age of the combined group of participants was 78 years, with a relatively high mean BMI of 28.6, a high mean hip-to-waist ratio of 1.06, and a moderate level of consumption of alcohol and fats [18] .
The cluster analysis for the SUCCAB measures suggested two clusters; the first containing 76 people with faster reaction times, while the second contained 17 people with relatively slow reaction times (see Appendix).
The cognitive assessments for the two SUCCAB clusters are depicted in Table 2 . A significant difference was evident between the clusters for all the SUCCAB tasks. Mean performance accuracy is included in Table 2 for illustrative purposes. Table 3 shows the comparison of the SUCCAB clusters in terms of age, total MedDietS, and average daily energy intake. These variables were used in subsequent analyses. Both clusters had a similar average age and there was no significant difference in MedDietS and daily energy intake (kJ) between the clusters. A cross tabulation test (Chi-squared ¼ 4.65, df ¼ 1, p ¼ 0.031) showed a significantly higher percentage of females in the slower reaction time cluster (91%) than the faster reaction time cluster (67%).
Cluster analysis of medications prescribed, using binary data suggested four clusters (see Fig. 3 ). Fewer medications were taken by those in Cluster M1 than those in the other clusters (t(89) ¼ 7.82, p < 0.001). Seventy-five percent of participants were using more than two medications, and 24% were taking more than five medications.
Details of the four clusters are explained in Table 4 . The major medication groups within each group are shown as percentages.
Cluster M1 was a relatively healthy group, of whom 41.4% took blood pressure medication and 27.6% took omega-3 long chain fatty acids. With 13.8% on blood thinners and 3.4% taking cholesterol lowering drugs, it may suggest that general practitioners are taking precautionary measures for this group. Cluster M2, the group with reflux concerns had a moderate-tohigh number of blood pressure medications, at 66.7%, pain medications, at 72.2%, and ulcer/reflux/protein pump inhibitors (83.3%). The high prescription of anti-ulcer drugs (H2 agonists) and protein pump inhibitors (PPIs) suggests that these patients are being treated for gastro-oesophageal reflux disease. This condition may lead to physical complications or symptoms that impact on wellbeing and quality of life; hence the substantial pain medication usage of 72.2%.
Cluster M3, the group with bone concerns. This group comprised mainly women, and had a moderate-to-high number of blood pressure medication (77.8%), omega-3 supplementation (44.4%), calcium supplements (55.6%), and vitamin D (100%). This was a very clear indication that they are being treated for osteopenia or osteoporosis.
Cluster M4, the cardio-compromised group, who had the highest number of blood pressure medication, at 89.3%, blood thinners, at 53.6%, and cholesterol lowering medication, at 96.4%, indicating that they are potentially being treated for coronary heart disease and/or metabolic syndrome. Although the medications taken by this cluster suggest that this group is cardiocompromised, Fig. 4 shows that they demonstrate a much faster cognitive reaction speed, which may be due in part to their medications potentially being cognitively protective.
The relationship between the cognitive speed clusters and medication clusters was found to be significant (Chisquared ¼ 10.63, df ¼ 3, p ¼ 0.014). As shown in Fig. 4, overall 18 .3% of participants were assigned to the slow reaction time cluster, with the lowest percentage (3.6%) of these from the cardiocompromised medication cluster, a relatively low percentage (13.8%) from the relatively healthy medication cluster, rising to 27.8% for the reflux concern cluster and 38.9% for the bone concern medication cluster.
It is notable that Cluster M4, the group with the highest proportional use of blood pressure medications (angiotensin blocking drugs), and highest use of statins and blood thinners is well Note: *p < 0.05, **p < 0.01, ***p < 0.001. represented in the fastest reaction time cluster (96.4%), while the relatively healthy cluster is less well represented in this cluster.
Binary logistic regression analysis for the SUCCAB clusters
The use of binary logistic regression is appropriate for predicting cognitive clusters as only two SUCCAB clusters were used, enabling us to explain the relationship between the SUCCAB clusters and the other variables of interest.
The assessment is staged. The control variables entered at Stage 1. The results given in Table 5 represent the control variables entered at Stage 1 and demonstrate no significant difference between the SUCCAB clusters in daily energy consumption, age and gender.
Stage 2 analyses are shown in Table 6 , indicating that when the MedDietS is included, the average daily energy intake is significant with respect to the cognition clusters. The odds ratio of 1.33 suggests that for every additional kilojoule of average daily intake, the odds of belonging to the slower reaction time cluster increase by 33% on average when age, gender and MedDietS are controlled for. Although the MedDietS is trending to significance, average daily energy intake is the only significant predictor of SUCCAB cluster at Stage 2.
Stage 3 analysis included the medication clusters. Table 7 shows that when the medication clusters are included in the regression with the Cardio-Compromised (M4) cluster as the reference cluster, average daily energy intake and MedDietS are significant predictors for the SUCCAB clusters. In Table 7 , Cluster M4 (the cardiocompromised cluster) is regarded as the reference category as this was the fastest reaction time group and it allowed for ease of interpretation. The odds ratio of 1.533 for average daily intake suggests that for every additional kilojoule, the odds of belonging to the slower reaction time cluster increase by 53% on average when age, gender, MedDietS and medication cluster are controlled for. The odds ratio of 0.573 for the MedDietS suggests that for every additional unit on the MedDietS the odds of belonging to the slower reaction time cluster decline by 43% on average when age, gender, average daily intake and medication cluster are controlled for. The odds ratio of 11.87 for the reflux concern cluster (M2) suggests that participants in this cluster are on average 11.87 times more likely than participants in the cardio-compromised cluster to fall into the for the bone concern cluster (M3) suggests that participants in this cluster are on average 33.25 times more likely than participants in the cardio-compromised cluster (M4), to fall in the slower reaction time cluster when these variables are controlled for. The summary of these results is shown in Table 8 , suggesting that the effect of age and gender are not significant, while it appears that the effect of the MedDiet was suppressed until Stage 3 when medications were controlled for. Interestingly if the medication cluster is not taken into consideration, we do not see a significant effect of the MedDietS on cognitive outcomes.
The summary of results in Table 8 demonstrates that when the medication use is taken into consideration, a higher MedDietS is associated with a faster response during the performance of cognitive tasks, particularly with respect to immediate recognition and spatial working memory, which are the major discriminating variables for the two cognitive clusters. In addition, it was found that the cardio-compromised participants in Cluster 4, who were taking higher levels of blood pressure and statin medications, are more likely to have faster response times than participants in medication clusters M2 and M3, the reflux concerns and bone concerns clusters, but similar response times to participants in cluster M1, the relatively healthy cluster. The Hosmer Lemeshow test indicates that the final model describes the data well (Chisquare ¼ 4.44, df ¼ 8, p ¼ 0.816), confirming that medication cluster needs to be accounted for when considering the relationship between MedDietS and cognition.
Discussion
Previous research has suggested that adherence to a Mediterranean diet has the potential to improve cognition, reduce cognitive impairment and cognitive decline and reduce the incidence of dementia [19e23] . However, a high prevalence of medication use in older individuals may also act to enhance, and preserve cognitive function in the longer term. Conversely medications may undermine cognitive function and any benefits afforded by adherence to a healthier diet. Previous studies have not considered these potential confounding effects of medications on MedDietecognition relationships.
The aim of this study was to investigate the association between adherence to a Mediterranean style diet and cognition in cognitive intact older adults living independently, and to determine the impact of medication use on cognitive outcomes. Based on previous findings it was expected that those with higher adherence to a MedDiet would show faster reaction times on the cognitive tasks performed [23] . As the MedDietS values only showed a trend to significance, we further investigated, potential confounding influences of medication use. It was postulated that the medications taken by the participants may influence their MedDietS, and subsequently, their cognitive reaction time assessments. In fact, without taking into consideration the impact of medications, we were unable to demonstrate the association between adherence to a MedDiet and cognitive outcomes.
All the participants in the present study had been assessed as cognitively healthy and were living independently in aged care and retirement villages. At the time of assessment their potential underlying medical conditions had been managed by their medical practitioner and where required, prescribed particular medications to normalise their conditions in order to control the underlying identified comorbidities.
A large proportion of the participants in our trial had been prescribed various antihypertensive drugs such as, angiotensin econverting enzyme inhibitors (ACE), diuretics (D), beta-blockers (BB), and angiotensin receptor blockers (ARB). In the "cardiocompromised group," 89% of participants were using an ACE, ARB, D or BB medications. Interestingly, this cardio-compromised group had the fastest response times as compared with the other medication clusters and were comparatively similar to the "Relatively healthy" cluster. A recent network meta-analysis compared antihypertensive drugs with respect to the incidence of dementia and cognitive function, demonstrating that all antihypertensive drugs may to some extent be cognitively protective; in particular ARB's showed significant benefits to cognitive functioning compared with placebo [24] . Further studies need to be conducted to substantiate our current results with regard to antihypertensive drugs and cognitive performance.
High levels of midlife total cholesterol have been associated with compromised late life episodic memory, slower psychomotor speed [25e27] and a higher risk of Alzheimer's disease (AD) [28] . It would therefore be expected that the maintenance of lower cholesterol levels through statin use (44% overall and 96% in the cardio-compromised group), would also confer ongoing benefits to cognitive health [29, 30] . However, a number of studies also indicate that statin medications may themselves impact adversely on cognition, possibly through side effects including increased physical and mental fatigue [31, 32] . While prescribed medications are critical for ongoing patient medical care, these other factors may act to confound the understanding of dietecognition relationships. Clearly more research is needed to better understand positive and negative impacts on cognitive health of both antihypertensive and statins medications; dosage, duration and different drug classes.
A relatively large proportion (25%) of participants in the cardiocompromised cluster were also taking antidepressant medications. Research suggests that these medications have a significant positive effect on psychomotor speed and delayed memory recall [33] and no adverse impact on the risk of cognitive decline leading to dementia [34] . Pain medication usage was high within the reflux group (72%) and may explain the slower reaction times observed in this cluster. Previous studies that have evaluated pain experiences, such as radicular or neuropathic pain, reported a basic slowing of reaction times. For example, slowing was observed in relation to incongruent and congruent Stroop stimuli trials, irrespective of other comorbidities and pain medication [35, 36] . Research within this area is complex and further focused cognitive clinical research needs to be conducted to gain a clearer understanding of pain and related pain therapy and relationships with cognition [36] .
Overall this study has found that when medication use was taken into consideration, that a higher adherence to a MedDiet is associated with faster cognitive reaction times. Interestingly the cardio-compromised group was the cluster with the fastest response times; suggesting that the medications also acted to normalise cognitive function. However, there may be other instances where medication use may have adversely affected cognition; this premise requires further investigation.
The participants in this study were screened as cognitively healthy e a key inclusion criterion for entry into the present study. Through analysis of medication clusters it has become apparent that cognitive status may also depend on medication use and that this is an important factor to take into account when considering the impact of diet on cognitive status. The alternative is to exclude all individuals that are taking medications from similar studies. As observed in our sample, there is a very high prevalence of medication use in older, independently living Australians. Excluding individuals taking medications would result in a sample that is not representative of the general population. Instead, we suggest that medication use be recorded and included in statistical analysis. Moreover, we suggest that previous studies in older cohorts that were not able to establish a relationship between MedDiet adherence and cognition may have been confounded by medication use.
Strengths and limitations
A key strength of this study is that the population of participants recruited were cognitively healthy and living in a homogenous environment, yet the profile of medications was diverse. All participants were tested within their own independent living facilities reducing potential confounding effects of travel time and assessment within an unfamiliar University setting. Age-sensitive computerised cognitive assessments were used to investigate dietary influences of a MedDiet, taking medications into account.
A limitation of the study is the disproportionate sampling of women (70%) compared with men, a characteristic that is typical of independent living and aged care facilities in Australia [37] . Gender was considered as a control variable in our statistical analysis but did not significantly impact on relationships. Nevertheless, future studies should aim to achieve a gender balance in their cohorts. A further limitation of the current study is that medication dosage and duration was not assessed; only type of medication was recorded given that this was a secondary outcome of the study. Future studies may consider more specific aspects of medication usage, including the class of drug, dosage and length of medication use.
Summary and conclusion
This study of a random selection of participants living independently within aged care facilities has demonstrated that those who have a higher MedDietS perform faster on cognitive assessments only when medication use has been taken into account. Previous research has suggested that medications act to normalise health and potentially stabilize cognitive function, however, no previous studies have taken medications into account when considering the association between adherence to a MedDiet and cognitive performance. Larger cross sectional and longitudinal studies need to be conducted to properly evaluate this proposition.
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